Biophytis presented its Phase 2-3 COVA study results in severe forms of
Covid-19 at the WCID in Paris

   Biophytis / Key word(s): Miscellaneous
   Biophytis presented its Phase 2-3 COVA study results in severe
   forms of Covid-19 at the WCID in Paris
   01-Jul-2024 / 07:00 CET/CEST
     ____________________________________________________________

   Biophytis presented its Phase 2-3 COVA study results in severe
   forms of Covid-19 at the WCID in Paris

   Paris (France) and Cambridge (Massachusetts, USA), July 01st,
   2024 - 07:00am CET - Biophytis SA (Euronext Growth Paris :
   ALBPS), ("Biophytis" or the "Company"), a clinical-stage
   biotechnology company specialized in the  development of
   therapeutics for age-related diseases,  presented the roll-out
   and results of its phase 2/3 COVA study in the treatment of
   severe forms of Covid-19 at the 6th edition of the World Congress
   on Infectious Diseases, held from June 24 to 26, 2024 in Paris,
   France.

   Professor Valerie Pourcher MD, PhD, Chaiman of the Infectious
   Diseases department at Pitié Salpetriere, presented the COVA
   phase 2/3 clincial study results in a context where the number of
   Covid cases rises again. Dr. Claudia Ferreira MD, PhD, Medical
   Director at Biophytis, opened the conference with a keynote
   presentation on the risk of infectious diseases and further
   pandemic developments associated with the Paris Olympic games
   including an increase of +52 %  in emergency room (ER) visits due
   to SARS-CoV-2 on the week of 10-17 June 2024 in France. She also
   chaired several roundtables.

   Valerie Pourcher detailed the results of the randomised,
   placebo-controlled Phase 2/3 COVA study and the efficacy of oral
   BIO101 (20-hydroxyecdysone) administered orally in adult patients
   hospitalised for severe forms of COVID-19.

   The results of this phase 2-3 study, evaluating BIO101 in the
   treatment of severe hospitalised COVID-19 patients, are positive
   and show, in addition to a very good safety profile, a
   statistically significant reduction in the relative risk of early
   respiratory failure or death of 43.8% and a 44.6% reduction in
   the death rate over 90 days.

   Stanislas Veillet, CEO of Biophytis, stated: " The Covid pandemic
   is far from over: according to the World Health Organization,
   134,797 new cases of Covid-19 and 1,691 deaths have been reported
   worldwide in the last 28 days as of June 9 - a figure that is
   underestimated due to under-reporting. Our COVA program, which
   showed very positive resullts, positions BIO101
   (20-hydroxyecdysone) as a leading  drug candidate for severe
   forms of Covid-19, particularly in elderly patients with
   co-morbidities, that is independent of the SARS-COV2 strain."

   The poster presented at the Congress, which details the
   objectives, the design and the results of the study, can be
   viewed by clicking on this link.

* * * *

About BIOPHYTIS

   Biophytis SA is a clinical-stage biotechnology company
   specializing in the development of drug candidates for
   age-related diseases. BIO101 (20-hydroxyecdysone), our lead drug
   candidate, is a small molecule in development for muscular
   (sarcopenia, phase 3 ready and Duchenne muscular dystrophy),
   respiratory (Covid-19 phase 2-3 completed) and metabolic diseases
   (obesity, phase 2 to be started). The company is based in Paris,
   France, and Cambridge, Massachusetts. The Company's ordinary
   shares are listed on Euronext Growth (Ticker: ALBPS -ISIN:
   FR0012816825). For more information, visit www.biophytis.com

Forward-looking statements

   This press release contains forward-looking statements.
   Forward-looking statements include all statements that are not
   historical facts. In some cases, you can identify these
   forward-looking statements by the use of words such as
   "outlook,"  "believes,"  "expects,"  "potential,"  "continues,"
   "may,"  "will,"  "should,"  "could,"   "seeks," "predicts,"
   "intends," "trends," "plans," "estimates," "anticipates" or the
   negative version of these   words or other comparable words. Such
   forward-looking statements are based on assumptions that
   Biophytis considers to be reasonable.  However, there can be no
   assurance that the statements contained in such forward-looking
   statements will be verified, which are subject to various risks
   and uncertainties. The forward- looking statements contained in
   this press release are also subject to risks not yet known to
   Biophytis or not currently considered material by Biophytis.
   Accordingly, there are or will be important factors that could
   cause actual outcomes or results to differ materially from those
   indicated in these statements. Please also refer to the "Risk and
   uncertainties the Company is to face» section from the Company's
   2023 Financial Report available on BIOPHYTIS website
   (www.biophytis.com) and as exposed in the "Risk Factors" section
   of form 20-F as well as other forms filed with the SEC
   (Securities and Exchange Commission, USA). We undertake no
   obligation to publicly update or review any forward-looking
   statement, whether as a result of new information, future
   developments or otherwise, except as required by law.

Biophytis contacts


Investor relations

Nicolas Fellmann, CFO

Investors@biophytis.com


Media

Antoine Denry: antoine.denry@taddeo.fr - +33 6 18 07 83 27

Nizar Berrada: nizar.berrada@taddeo.fr - +33 6 38 31 90 50

____________________________________________________________

   Dissemination of a Financial Wire News, transmitted by EQS Group.
   The issuer is solely responsible for the content of this
   announcement.
     ____________________________________________________________

   Language:    English
   Issuer:      Biophytis
                14 avenue de l´Opéra
                75001 Paris
                France
   Internet:    https://www.biophytis.com
   ISIN:        US09076G1040, FR0012816825
   EQS News ID: 1936247

   End of Announcement - EQS News Service
     ____________________________________________________________

1936247 01-Jul-2024 CET/CEST